Hormonal
GLP-1 Receptor Agonists (GLP-1RAs) improve glycemic control and promote weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.
GLP-1RAs help control blood sugar and promote weight loss by mimicking a gut hormone that tells your body to release insulin when needed, slows down digestion, and reduces appetite. They are generally safe regarding low blood sugar but can cause stomach issues initially. Consistent use and monitoring are key to managing side effects and achieving long-term health benefits.
GLP-1RAs enhance glycemic control through several mechanisms. Upon binding to GLP-1R on pancreatic beta cells, these agonists activate adenylyl cyclase, converting ATP into cAMP. Elevated cAMP levels activate PKA and exchange protein directly activated by cAMP (EPAC), both of which are pivotal in insulin secretion and glucose regulation [77].
Why this rating
Supported by multiple large-scale CVOTs (LEADER, SUSTAIN-6, REWIND, etc.).
Source
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano et al. · Biomedicines · 2024
DOI 10.3390/biomedicines12092039
More from this paper
- SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, resulting in glucosuria, with efficacy dependent on maintaining a filtered glucose load above 80g/day.Good
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to monotherapy by leveraging synergistic mechanisms of both incretin hormones.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →